Neurological Sciences

, Volume 38, Supplement 1, pp 201–206 | Cite as

Transcutaneous supraorbital neurostimulation for the prevention of chronic migraine: a prospective, open-label preliminary trial

  • Paola Di Fiore
  • Gennaro Bussone
  • Alberto Galli
  • Henri Didier
  • Cesare Peccarisi
  • Domenico D’Amico
  • Fabio Frediani


Since chronic migraine is difficult to treat and often associated with medication overuse, non-invasive neurostimulation approaches are worth investigating. Transcutaneous supraorbital neurostimulation using the Cefaly® device is promising as a non-invasive preventive treatment for episodic migraine, but no data are available for chronic migraine. Our aim was to perform a preliminary evaluation of the efficacy of the Cefaly® device for the prophylaxis of chronic migraine with or without medication overuse. Primary endpoints were 50% reduction in monthly migraine days and 50% reduction in monthly medication use over 4 months. In an open-label study, twenty-three consecutive headache center patients with chronic migraine, diagnosed according to International Headache Society criteria, were recruited prospectively. After informed consent, patients were trained to use Cefaly® and instructed to use it for 20 min daily over 4 months. All patients received active neurostimulation. Thirty-five percent of the patients enrolled in the study achieved the study endpoints. Over half the patients had a greater than 50% reduction in acute medication consumption.


Chronic migraine Migraine prophylaxis Medication overuse Transcutaneous supraorbital neurostimulation 


  1. 1.
    Natoli J, Manack A, Dean B et al (2010) Global prevalence of chronic migraine: a systematic review. Cephalalgia 30:599–609CrossRefPubMedGoogle Scholar
  2. 2.
    Evers S, Marziniak M (2010) Clinical features, pathophysiology, and treatment of medication-overuse headache. Lancet Neurol 9:391–401CrossRefPubMedGoogle Scholar
  3. 3.
    D’Amico D, Grazzi L, Usai S et al (2011) Disability in chronic daily headache: state of the art and future directions. Neurol Sci 32:S71–S76CrossRefPubMedGoogle Scholar
  4. 4.
    Manack AN, Buse DC, Lipton RB (2011) Chronic migraine: epidemiology and disease burden. Curr Pain Headache Rep 15:70–78CrossRefPubMedGoogle Scholar
  5. 5.
    Jürgens TP, Leone M (2013) Pearls and pitfalls: neurostimulation in headache. Cephalalgia 33:512–525CrossRefPubMedGoogle Scholar
  6. 6.
    Magis D, Schoenen J (2012) Advances and challenges in neurostimulation for headaches. Lancet Neurol 11:708–719CrossRefPubMedGoogle Scholar
  7. 7.
    Magis D, Jensen R, Schoenen J (2012) Neurostimulation therapies for primary headache disorders: present and future. Curr Opin Neurol 25:269–276CrossRefPubMedGoogle Scholar
  8. 8.
    Gallagher RM, Kunkel R (2003) Migraine medication attributes important for patient compliance: concerns about side effects may delay treatment. Headache 43:36–43CrossRefPubMedGoogle Scholar
  9. 9.
    Schoenen J, Vandersmissen B, Jeangette S et al (2012) Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial. Neurology 80:697–704CrossRefGoogle Scholar
  10. 10.
    Headache Classification Committee of the International Headache Society (IHS) (2013) The international classification of headache disorders, 3rd edition (beta version). Cephalalgia 33(9):629-808. doi:10.1177/0333102413485658 CrossRefGoogle Scholar
  11. 11.
    D’Amico D, Leone M, Grazzi L et al (2008) When should “chronic migraine” patients be considered “refractory” to pharmacological prophylaxis? Neurol Sci 29:S55–S58CrossRefPubMedGoogle Scholar
  12. 12.
    Mathew NT (2009) Dynamic optimization of chronic migraine treatment: current and future options. Neurology 72:S14–S20CrossRefPubMedGoogle Scholar
  13. 13.
    Andrasik F, Grazzi L, Usai S et al (2007) Disability in chronic migraine with medication overuse: treatment effects at 3 years. Headache 47:1277–1281CrossRefPubMedGoogle Scholar
  14. 14.
    Zwart JA, Dyb G, Hagen K et al (2003) Analgesic use: a predictor of chronic pain and medication overuse headache: the Head-HUNT study. Neurology 61:160–164CrossRefPubMedGoogle Scholar
  15. 15.
    Katsarava Z, Schneeweiss S, Kurth T et al (2004) Incidence and predictors for chronicity of headache in patients with episodic migraine. Neurology 62:788–790CrossRefPubMedGoogle Scholar
  16. 16.
    Bigal ME, Lipton RB (2009) What predicts the change from episodic to chronic migraine? Curr Opin Neurol 22:269–276CrossRefPubMedGoogle Scholar
  17. 17.
    Katsarava Z, Muessig M, Dzagnidze A et al (2005) Medication overuse headache: rates and predictors for relapse in a 4-year prospective study. Cephalalgia 25:12–15CrossRefPubMedGoogle Scholar
  18. 18.
    Bigal ME, Serrano D, Buse D et al (2008) Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache 48:1157–1168CrossRefPubMedGoogle Scholar
  19. 19.
    Bigal ME, Rapoport AM, Sheftell FD et al (2004) Transformed migraine and medication overuse in a tertiary headache centre-clinical characteristics and treatment outcomes. Cephalalgia 24:483–490CrossRefPubMedGoogle Scholar
  20. 20.
    Freitag FG, Lake A 3rd, Lipton R, US Headache Guidelines Consortium, Section on Inpatient Treatment Chairpersons et al (2004) Inpatient treatment of headache: an evidence-based assessment. Headache 44:342–360CrossRefPubMedGoogle Scholar
  21. 21.
    Zeeberg P, Olesen J, Jensen R (2006) Discontinuation of medication overuse in headache patients: recovery of therapeutic responsiveness. Cephalalgia 26:1192–1198CrossRefPubMedGoogle Scholar
  22. 22.
    Saper JR, Lake AE 3rd, Cantrell DT et al (2002) Chronic daily headache prophylaxis with tizanidine: a doubleblind, placebo-controlled, multicenter outcome study. Headache 42:470–482CrossRefPubMedGoogle Scholar
  23. 23.
    Spira PJ, Beran RG, Australian Gabapentin Chronic Daily Headache Group (2003) Gabapentin in the prophylaxis of chronic daily headache: a randomized, placebo-controlled study. Neurology 61:1753–1759CrossRefPubMedGoogle Scholar
  24. 24.
    Yurekli VA, Akhan G, Kutluhan S et al (2008) The effect of sodium valproate on chronic daily headache and its subgroups. J Headache Pain 9:37–41CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Mei D, Ferraro D, Zelano G et al (2006) Topiramate and triptans revert chronic migraine with medication overuse to episodic migraine. Clin Neuropharmacol 29:269–275CrossRefPubMedGoogle Scholar
  26. 26.
    Silvestrini M, Bartolini M, Coccia M et al (2003) Topiramate in the treatment of chronic migraine. Cephalalgia 23:820–824CrossRefPubMedGoogle Scholar
  27. 27.
    Diener HC, Bussone G, Van Oene JC, TOPMAT-MIG-201(TOP-CHROME) Study Group et al (2007) Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 27:814–823CrossRefPubMedGoogle Scholar
  28. 28.
    Silberstein S, Lipton RB, Dodick DW et al (2007) Efficacy and safety of topiramate in the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache 47:170–180CrossRefPubMedGoogle Scholar
  29. 29.
    Silberstein SD, Blumenfeld AM, Cady RK et al (2013) OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. J Neurol Sci 331:48–56CrossRefPubMedGoogle Scholar
  30. 30.
    Dodick DW, Turkel CC, DeGryse RE, PREEMPT Chronic Migraine Study Group et al (2010) OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 50:921–936CrossRefPubMedGoogle Scholar
  31. 31.
    Aurora SK, Dodick DW, Turkel CC, PREEMPT 1 Chronic Migraine Study Group et al (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 30:793–803CrossRefPubMedGoogle Scholar
  32. 32.
    Diener HC, Dodick DW, Aurora SK, PREEMPT 2 Chronic Migraine Study Group et al (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 30:804–814CrossRefPubMedGoogle Scholar
  33. 33.
    Leone M, Franzini A, Bussone G (2001) Stereotactic stimulation of posterior hypothalamic gray matter in a patient with intractable cluster headache. N Engl J Med 345:1428–1429CrossRefPubMedGoogle Scholar
  34. 34.
    Lambru G, Matharu MS (2014) Peripheral neurostimulation in primary headaches. Neurol Sci 35:77–81CrossRefPubMedGoogle Scholar
  35. 35.
    Saper JR, Dodick DW, Silberstein SD et al (2011) Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study. Cephalalgia 31:271–285CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Bartsch T, Paemeleire K, Goadsby PJ (2009) Neurostimulation approaches to primary headache disorders. Curr Opin Neurol 22:262–268CrossRefPubMedGoogle Scholar
  37. 37.
    Popeney CA, Alo´ KM (2003) Peripheral neurostimulation for the treatment of chronic, disabling transformed migraine. Headache 43:369–375CrossRefPubMedGoogle Scholar
  38. 38.
    Dodick DW, Silberstein SD, Reed KL et al (2015) Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: long-term results from a randomized, multicenter, double-blinded, controlled study. Cephalalgia 35:344–358CrossRefPubMedGoogle Scholar
  39. 39.
    Tepper SJ, Rezai A, Narouze S et al (2009) Acute treatment of intractable migraine with sphenopalatine ganglion electrical stimulation. Headache 49:983–989CrossRefPubMedGoogle Scholar
  40. 40.
    Noseda R, Burstein R (2013) Migraine pathophysiology: anatomy of the trigeminovascular pathway and associated neurological symptoms, cortical spreading depression, sensitization, and modulation of pain. Pain 154:S44–S53CrossRefPubMedGoogle Scholar
  41. 41.
    Bartsch T, Goadsby PJ (2003) The trigeminocervical complex and migraine: current concepts and synthesis. Curr Pain Headache Rep 7:371–376CrossRefPubMedGoogle Scholar
  42. 42.
    Matharu MS, Bartsch T, Ward N et al (2004) Central neuromodulation in chronic migraine patients with suboccipital stimulators: a PET study. Brain 127:220–230CrossRefPubMedGoogle Scholar
  43. 43.
    D’Amico D (2010) Pharmacological prophylaxis of chronic migraine: a review of double-blind placebo-controlled trials. Neurol Sci 31:S23–S28 (369–375) CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia 2017

Authors and Affiliations

  • Paola Di Fiore
    • 1
  • Gennaro Bussone
    • 2
  • Alberto Galli
    • 1
  • Henri Didier
    • 3
  • Cesare Peccarisi
    • 4
  • Domenico D’Amico
    • 5
  • Fabio Frediani
    • 1
  1. 1.Neurological and Stroke Unit Department, Headache Center, ASST Santi Paolo e CarloSan Carlo Borromeo HospitalMilanItaly
  2. 2.C. Besta Neurological Institute IRCCS Foundation and Igea Healthcare InstituteMilanItaly
  3. 3.Maxillo-Facial and Dental Unit, Dental and Oral Surgery, Headache and Facial Pain Center, IRCCS Foundation Ca’ Granda, Ospedale Maggiore PoliclinicoUniversity of MilanMilanItaly
  4. 4.LIMPE-DISMOV AcademyUniversity La SapienzaRomeItaly
  5. 5.Headache CenterCarlo Besta Neurological Institute and FoundationMilanItaly

Personalised recommendations